NCT05621837 2025-05-02SerpentineFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruiting1,000 enrolled
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA